Image_2_Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis.tif
The aim of this study is to investigate the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in assessing the poor outcomes of adult patients with acute myocarditis.
MethodsA total of 170 adult patients with available NT-proBNP information were included in the study. They were grouped according to quartiles of NT-proBNP concentrations at admission. Baseline and follow-up information was collected. Thirty-day major adverse cardiac events (MACE) were death and heart transplantation. Long-term MACE included all-cause death, heart transplantation, re-hospitalization due to heart failure, sustained ventricular arrhythmia, and myocarditis relapse.
ResultsDuring a median follow-up of 3.8 years, patients in the highest NT-proBNP quartile suffered from the highest risk both of 30-day and long-term MACE (P < 0.001 by log-rank test). Multivariate analysis showed that apart from left ventricular ejection fraction (LVEF), an increased baseline NT-proBNP > 3,549 pg/mL (hazard ratio 3.535, 95% CI 1.316–9.499, P = 0.012) and NT-proBNP > 7,204 pg/mL (hazard ratio 22.261, 95% CI 1.976–250.723, P = 0.012) was independent predictor of long-term and 30-day MACE, respectively.
ConclusionsHigher baseline NT-proBNP level was an independent predictor of poor outcomes in adult patients with acute myocarditis. Therefore, NT-proBNP may serve as a useful biomarker for risk stratification in acute myocarditis patients.
History
References
- https://doi.org//10.1093/eurheartj/ehm076
- https://doi.org//10.1093/eurheartj/eht210
- https://doi.org//10.1161/CIR.0000000000000745
- https://doi.org//10.1161/CIRCULATIONAHA.118.035319
- https://doi.org//10.1093/eurjhf/hfq229
- https://doi.org//10.1111/anec.12726
- https://doi.org//10.6515/acs20150226a
- https://doi.org//10.1161/CIRCULATIONAHA.117.026386
- https://doi.org//10.1016/j.jacc.2017.08.044
- https://doi.org//10.1016/j.jacc.2017.08.050
- https://doi.org//10.1093/eurheartj/ehw128
- https://doi.org//10.1093/eurheartj/ehz394
- https://doi.org//10.1056/NEJMoa042330
- https://doi.org//10.1001/jamacardio.2020.1017
- https://doi.org//10.1186/s12931-020-01352-w
- https://doi.org//10.1002/jmv.25809
- https://doi.org//10.1016/j.jacc.2009.02.007
- https://doi.org//10.1016/j.carpath.2011.10.001
- https://doi.org//10.1161/CIR.0000000000000490
- https://doi.org//10.1093/eurheartj/eht466
- https://doi.org//10.1042/CS20040087
- https://doi.org//10.1016/j.jacc.2019.04.063
- https://doi.org//10.1161/CIRCULATIONAHA.113.003092
- https://doi.org//10.1161/CIRCULATIONAHA.108.769489
- https://doi.org//10.1016/j.tcm.2020.05.008
- https://doi.org//10.1016/S0140-6736(11)60648-X
- https://doi.org//10.1016/0002-8703(94)90483-9
- https://doi.org//10.12998/wjcc.v7.i5.548
- https://doi.org//10.1016/j.amjcard.2014.11.029
- https://doi.org//10.7860/JCDR/2016/19856.7967
- https://doi.org//10.12998/wjcc.v8.i22.5547
- https://doi.org//10.1002/ejhf.1771
- https://doi.org//10.1007/s00392-010-0140-z
- https://doi.org//10.1016/S0828-282X(06)70908-4
- https://doi.org//10.1016/j.cellsig.2010.03.009
- https://doi.org//10.1002/jcp.20307
- https://doi.org//10.1177/147323000403200109
- https://doi.org//10.1161/CIRCHEARTFAILURE.119.006570
- https://doi.org//10.1038/nrcardio.2015.108
- https://doi.org//10.1001/jamacardio.2020.1096
- https://doi.org//10.1038/s41392-020-00360-y
CC BY 4.0